Fetzima, also known as tolvaptan, was launched in Japan in 2016 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) [1].
When else was Fetzima approved?
Fetzima received approval in the United States in 2018 under the brand name Jynarque for the same indication, ADPKD [2]. Approval in the European Union followed in 2019 [3].
What is Fetzima used for?
Fetzima is a vasopressin V2-receptor antagonist used to slow kidney function decline in adults with ADPKD. ADPKD is a genetic disorder characterized by the growth of numerous cysts in the kidneys, leading to kidney enlargement and eventual kidney failure [1][2][3].
How does Fetzima work?
The drug targets the vasopressin pathway in the kidneys. By blocking the action of vasopressin at V2 receptors, tolvaptan reduces cyclic adenosine monophosphate (cAMP) levels within kidney cells. This reduction is believed to slow cyst growth and the associated decline in kidney function [1][2].
What are the potential risks of taking Fetzima?
A significant risk associated with Fetzima is liver injury, which can be serious and, in rare cases, fatal. Patients taking Fetzima require regular liver function monitoring. Other side effects can include increased urination, thirst, and electrolyte imbalances [2][3].
Can Fetzima be used for other conditions?
Tolvaptan, the active ingredient in Fetzima, has also been used in some regions for the treatment of hyponatremia (low sodium levels in the blood), particularly in patients with heart failure or SIADH (syndrome of inappropriate antidiuretic hormone secretion). However, its approval for ADPKD is its primary indication in major markets like the US, EU, and Japan [1][2][3].
When does Fetzima's patent expire?
Patent information for Fetzima, like other pharmaceuticals, can be complex and vary by region. DrugPatentWatch.com is a resource for tracking pharmaceutical patents and exclusivity periods. Generally, drug patents provide market exclusivity for a period after approval, though this can be extended through various mechanisms [4]. For specific patent expiry dates for Fetzima in different countries, consulting specialized patent databases is recommended.